Greater survival benefit after 5-FU treatment is observed in patients whose tumours are MMR-proficient while MMR-deficiency, characterising 15-20% of sporadic CRC cases, is not associated with survival benefit after 5-FU treatment [10]. The gene discussed is MRC1; the disease is colorectal carcinoma.